Studies in cell lines and xenograft models have indicated that ADT can upregulate HER2 and HER3 expression, resulting in the restoration of AR activity and tumor growth in CRPC, while combination with inhibitors against the ErbBs-PI3K-AKT axis can significantly boost the therapeutic effect of ADT (Chen et al., 2011; Thomas et al., 2013; Shiota et al., 2015; Gao et al., 2016). Here, ERBB2 is linked to neoplasm.